Using xpert MTB/RIF

Current Respiratory Medicine Reviews

Volumn 9, Issue 3, 2013, Pages 187-192

  Nicol, Mark P ^a,b   Whitelaw, Andrew ^b,c   Stevens, Wendy ^b,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Cost effectiveness; Detection; Diagnosis; Rifampicin; Tuberculosis; Xpert MTB RIF

Indexed keywords

RIFAMPICIN;

ARTICLE; AUTOMATED REAL TIME POLYMERASE CHAIN REACTION TEST; CLINICAL EVALUATION; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; EXTRAPULMONARY TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MEDICAL DEVICE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POINT OF CARE TESTING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; TUBERCULOSIS;

EID: 84888103728     PISSN: 1573398X     EISSN: 18756387     Source Type: Journal    
DOI: 10.2174/1573398X113099990015     Document Type: Article

References (51)

1. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva: World Health Orgnization, 2011.
2. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300(4): 423-30.
3. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363(11): 1005-15.
4. Scott LE, McCarthy K, Gous N, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS medicine 2011; 8(7): e1001061.
5. Teo J, Jureen R, Chiang D, Chan D, Lin R. Comparison of two nucleic acid amplification assays, the Xpert MTB/RIF assay and the amplified Mycobacterium Tuberculosis Direct assay, for detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J Clin Microbiol 2011; 49(10): 3659-62.
6. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, nearpatient technology. J Clin Microbiol 2010; 48(1): 229-37.
7. El-Hajj HH, Marras SA, Tyagi S, Kramer FR, Alland D. Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons. J Clin Microbiol 2001; 39(11): 4131-7.
8. Lawn SD, Nicol MP. Xpert(R) MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 2011; 6(9): 1067-82.
9. Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 2010; 48(7): 2495-501.
10. Banada PP, Sivasubramani SK, Blakemore R, et al. Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. J Clin Microbiol 2010; 48(10): 3551-7.
11. Steingart KR, Sohn H, Schiller I, et al. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013; 1: CD009593.
12. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377(9776): 1495-505.
13. FIND Report: Performance of Xpert MTB/RIF Version G4 Assay. Geneva, 2011 20 November 2011.
14. Simpson JA, Caldwell J, Bosman M, Osman M. GeneXpert rifampicin resistance-experiences from the field. 3rd South African Tuberculosis Congress. Durban, 2012.
15. Zar HJ, Workman L, Isaacs W, et al. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2012; 55(8): 1088-95.
16. Rachow A, Zumla A, Heinrich N, et al. Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study. PloS one 2011; 6(6): e20458.
17. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011; 11(11): 819-24.
18. Bates M, O'Grady J, Maeurer M, et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis 2013; 13(1): 36-42.
19. Xpert MTB/RIF increases timely TB detection among people living with HIV and saves lives: Information note. In: Organization WH, 2013.
20. Schnippel K, Meyer-Rath G, Long L, Stevens WS, Sanne I, Rosen S. Diagnosing Xpert MTB/RIF negative TB: Impact and cost of alternative algorithms for South Africa. S Afr Med J 2013; 103(2): 101-6.
21. Rapid Implementation of the Xpert MTB/RIF diagnostic test: Technocal and Operational 'How-to' Practical Considerations. Geneva: World Health Organization, 2011.
22. Scott LE, Gous N, Cunningham BE, et al. Dried culture spots for Xpert MTB/RIF external quality assessment: results of a phase 1 pilot study in South Africa. J Clin Microbiol 2011; 49(12): 4356-60.
23. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS medicine 2012; 9(11): e1001347.
24. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a highvolume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177(7): 787-92.
25. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32(5): 1165-74.
26. Brossier F, Veziris N, Jarlier V, Sougakoff W. Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. Int J Tuberc Lung Dis 2009; 13(2): 260-5.
27. Dorman SE, Chihota VN, Lewis JJ, et al. Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. J Clin Microbiol 2012; 50(4): 1189-94.
28. Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol 2012; 50(11): 3712-6.
29. Barnard M, Warren R, Van Pittius NG, et al. Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drugresistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med 2012; 186(12): 1298-305.
30. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PloS one 2012; 7(3): e33275.
31. Ignatyeva O, Kontsevaya I, Kovalyov A, et al. Detection of resistance to second-line antituberculosis drugs by use of the genotype MTBDRsl assay: a multicenter evaluation and feasibility study. J Clin Microbiol 2012; 50(5): 1593-7.
32. Kontsevaya I, Ignatyeva O, Nikolayevskyy V, et al. Diagnostic accuracy of the genotype MTBDRsl assay for rapid diagnosis of extensively drug-resistant tuberculosis in HIV-coinfected patients. J Clin Microbiol 2013; 51(1): 243-8.
33. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48(5): 1683-9.
34. The Use of Molecular Line Probe Assay for the Detection of Resistance to Second-Line Anti-Tuberculosis Drugs: Expert Group Meeting Report. Geneva: World Health Organization, 2013, 2013.
35. Friedrich SO, von Groote-Bidlingmaier F, Diacon AH. Xpert MTB/RIF assay for diagnosis of pleural tuberculosis. J Clin Microbiol 2011; 49(12): 4341-2.
36. Ligthelm LJ, Nicol MP, Hoek KG, et al. Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens. J Clin Microbiol 2011; 49(11): 3967-70.
37. Tortoli E, Russo C, Piersimoni C, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012; 40(2): 442-7.
38. Lawn SD, Zumla AI. Diagnosis of extrapulmonary tuberculosis using the Xpert(R) MTB/RIF assay. Expert Rev Anti Infect Ther 2012; 10(6): 631-5.
39. Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Microbiol 2011; 49(7): 2540-5.
40. Whitelaw A, Peter J, Sohn H, et al. Comparative cost and performance of light-emitting diode microscopy in HIVtuberculosis-co-infected patients. Eur Respir J 2011; 38(6): 1393-7.
41. Rachow A, Clowes P, Saathoff E, et al. Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study. Clin Infect Dis 2012; 54(10): 1388-96.
42. Kim SY, Kim H, Kim SY, et al. The Xpert(R) MTB/RIF assay evaluation in South Korea, a country with an intermediate tuberculosis burden. Int J Tuberc Lung Dis 2012; 16(11): 1471-6.
43. Balcells ME, Garcia P, Chanqueo L, et al. Rapid molecular detection of pulmonary tuberculosis in HIV-infected patients in Santiago, Chile. Int J Tuberc Lung Dis 2012; 16(10): 1349-53.
44. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS medicine 2011; 8(11): e1001120.
45. Meyer-Rath G, Schnippel K, Long L, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PloS one 2012; 7(5): e36966.
46. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 2011; 204 Suppl 4: S1159-67.
47. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIVassociated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS medicine 2011; 8(7): e1001067.
48. Andrews JR, Lawn SD, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. Aids 2012; 26(8): 987-95.
49. GeneXpert Dx System Operator Manual, Software Version 4. 0. Cepheid, 2010.
50. Schnippel K, Meyer-Rath G, Long L, et al. Scaling up Xpert MTB/RIF technology: the costs of laboratory-vs clinic-based rollout in South Africa. Trop Med Int Health 2012; 17(9): 1142-51.
51. Clouse K, Page-Shipp L, Dansey H, et al. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J 2012; 102(10): 805-7.